全球组织工程市场规模、份额和成长分析：按材料、按用途- 产业预测（2023-2030）

Global Tissue Engineering Market Size, Share, Growth Analysis, By Material(Synthetic Material, and Biologically Derived Material), By Application(Cord blood & Cell Banking, Gynecology) - Industry Forecast 2023-2030

出版日期: 2023年09月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球组织工程市场规模预计将从 2022 年的 143.9 亿美元增至 2030 年的 324.5 亿美元，在预测期内（2023-2030 年）年复合成长率为 10.7%。

由于再生医学和器官移植的进步，市场呈现显着成长。由于器官移植需求的增加和慢性病的流行，市场正在扩大。该公司正在投资研究开发有效的组织工程解决方案，包括支架、生物材料和细胞疗法，以满足世界各地不断增长的医疗需求。

促进因素

包括心血管疾病、整形外科疾病和器官衰竭在内的慢性疾病的增加正在为组织工程部门提供重大推动力。组织工程为组织和器官重组提供了有前途的治疗方法，为患有持续性疾病的人提供了极好的替代选择。

市场趋势

全球组织工程产业面临法规障碍，包括与生物工程组织和细胞应用相关的安全性、有效性和伦理考量。严格的法规结构和广泛的核准程序可能会阻碍市场进步，从而限制组织工程产品和治疗方法的取得。

本报告针对全球组织工程市场进行研究与分析，提供市场动态与预测、細項分析、公司简介等。

Organogenesis Holdings Inc. (US)
Acelity LP Inc. (US)
Medtronic plc (Ireland)
Integra LifeSciences Corporation (US)
Stryker Corporation (US)
Zimmer Biomet Holdings, Inc. (US)
Baxter International Inc. (US)
Allergan plc (Ireland)
Smith & Nephew plc (UK)
Wright Medical Group NV (Netherlands)
Cook Medical Incorporated (US)
MiMedx Group, Inc. (US)
Osiris Therapeutics, Inc. (US)
Tissue Regenix Group plc (UK)
NuVasive, Inc. (US)
Cellular Dynamics International (US)
Vericel Corporation (US)
RepliCel Life Sciences Inc. (Canada)
Organovo Holdings, Inc. (US)
AlloSource (US)

简介目录

Product Code: SQMIG35H2087

Global Tissue Engineering Market size was valued at USD 13 Billion in 2021 and is poised to grow from USD 14.39 Billion in 2022 to USD 32.45 Billion by 2030, at a CAGR of 10.7% during the forecast period (2023-2030).

The global tissue engineering market is experiencing significant growth due to advancements in regenerative medicine and organ transplantation. This innovative field involves creating functional tissues using biocompatible materials, cells, and biochemical factors. With increasing demand for organ transplants and the rising prevalence of chronic diseases, the market is expanding. Companies are investing in research to develop effective tissue engineering solutions, including scaffolds, biomaterials, and cell therapies, to address the growing medical needs globally.

Top-down and bottom-up approaches were used to estimate and validate the size of tissue engineering and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Drivers

The uptick in chronic ailment occurrences, encompassing cardiovascular issues, orthopedic ailments, and organ insufficiencies, has significantly propelled the tissue engineering sector. Tissue engineering presents promising remedies for tissue and organ reconstruction, providing enhanced therapeutic alternatives for individuals grappling with persistent health conditions.

Restraints

Privacy and security issues emerge with the accumulation and examination of social media data, giving rise to apprehensions about data protection. The necessity for adherence to more stringent regulations and compliance protocols could present difficulties for providers of social media analytics in their task of managing and safeguarding user data.

Market Trends

The global tissue engineering industry encounters obstacles in terms of regulations encompassing the safety, effectiveness, and ethical considerations linked to the application of bioengineered tissues and cells. Stringent regulatory frameworks and extensive endorsement procedures have the potential to hinder the advancement of the market, thereby restricting the accessibility of tissue engineering offerings and treatments.